semaglutide when to see results The Pros and Cons of for Weight Loss Struggling to Lose Weight? How

Simultaneously, semaglutide suppresses glucagon secretion from pancreatic alpha cells, further contributing to improved glycemic control

Paresthesia is also cited as one of retatrutides representative adverse effects

17, 2025 /PRNewswire/ -- Novo Nordisk announced today that the US Food and Drug Administration (FDA) has approved Rybelsus , the only oral GLP-1 medication available, for reducing the risk of major adverse cardiovascular events (MACE) such as cardiovascular (CV) death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events, whether they've had a prior CV event or not (primary and secondary prevention)

The predominance of primary care prescribing suggests that the oral formulation may lower barriers to use outside of specialty care, aligning with its potential to broaden access to obesity treatment

Longer-term data are required to validate these results